Is Enliven Therapeutics, Inc. (ELVN) a Buy, Sell, or Hold?
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$51.73 USD
$0.86 (1.69%)
- Volume
- 950.21K
- Average Volume
- 1.33M
- Market Capitalization
- $3.7B
- P/E Ratio
- -31.54
- Dividend Yield
- 0.00%
- Price Target
- $65.00
- Year High
- $52.39
- Year Low
- $14.79
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $40.32
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Richard A. Fair |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ELVN |
| CUSIP | 29337E102 |
| CIK | 0001672619 |
| Web | https://www.enliventherapeutics.com |
| Phone | 720 647 8519 |
| Currency | USD |
| Employees | 61 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 40.32 |
| Quick Ratio | 40.32 |
| Cash Ratio | 11.51 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.04 |
| Price / Cash Flow | -56.33 |
| Price / Book | 7.17 |
Price Target and Rating
| Average Stock Price Forecast | $65.00 |
| High Stock Price Forecast | $80.00 |
| Low Stock Price Forecast | $59.00 |
| Forecast Upside/Downside | -20.42% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.83 |
| Trailing P/E Ratio | -31.54 |
| PEG Ratio | -2.12 |
| P/E Growth | -2.12 |
| Net Income | $-103.69M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -21.04% |
| Return on Assets | -21.25% |
Financials Score
| AltmanZ Score | 189.17 |
| Piotroski Score | 2.00 |
| Working Capital | 451.65M |
| Total Assets | 464.85M |
| Ebit | -98.78M |
| Market Cap | 3.63B |
| Total Liabilities | 11.49M |
Poll Results
About Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado. ...
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
2026-06-27 15:36:42
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
2026-06-27 12:03:12
Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction represented 11.60% of Advisors Llc Orbimed's total indirect holdings, reducing indirect ownership from 7,415,225 to 6,555,102 shares.
2026-06-15 16:40:00
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.
2026-06-11 23:00:00
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
2026-06-11 22:39:00
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven's common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-06-11 16:05:00
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock.
2026-06-11 14:42:09
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
2026-06-11 08:00:00
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Favorable safety and tolerability profile with 161 patients enrolled and a median treatment duration of 35 weeks Alignment with the FDA on 80 mg QD as the recommended Phase 3 dose and on the 2L+ patient population for the ENABLE-2 pivotal trial, which is expected to initiate in the second half of this year BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today presented updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML).
Frequently Asked Questions
-
What is the current Enliven Therapeutics, Inc. (ELVN) stock price?
-
Enliven Therapeutics, Inc.(NASDAQ:ELVN) stock price is $51.73 in the last trading session. During the trading session, ELVN stock reached the peak price of $52.39 while $14.785 was the lowest point it dropped to. The percentage change in ELVN stock occurred in the recent session was 1.69% while the dollar amount for the price change in ELVN stock was $0.86.
-
ELVN's industry and sector of operation?
-
The NASDAQ listed ELVN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ELVN?
-
Damiette Smit | Vice President of Clinical Development
Samuel S. Kintz | Co-Founder & Head of Pipeline
Joseph Lyssikatos | Co-Founder & Research Fellow
Benjamin Hohl | Chief Financial Officer & Head of Corporate Development
Richard A. Fair | CEO, President & Director -
How many employees does ELVN have?
-
Number of ELVN employees currently stands at 61. ELVN operates from 6200 Lookout Road, Boulder, CO 80301, US.
-
Link for ELVN official website?
-
Official Website of ELVN is: https://www.enliventherapeutics.com
-
How do I contact ELVN?
-
ELVN could be contacted at phone #720 647 8519 and can also be accessed through its website. ELVN operates from 6200 Lookout Road, Boulder, CO 80301, US.
-
How many shares of ELVN are traded daily?
-
The average number of ELVN shares traded daily for last 3 months was 1.33M.
-
What is the market cap of ELVN currently?
-
The market value of ELVN currently stands at $3.7B with its latest stock price at $51.73